Does pre-chemotherapy extent of nodal involvement impact your decision to offer adjuvant radiation in cN1, ypN0 triple-negative breast cancer?  

E.g., does the quantity of clinically involved nodes, the size of involved nodes or extent of ENE prior to neoadjuvant chemotherapy and mastectomy impact your radiation decision making with ypN0 disease?